Post-COVID-19 Condition (long COVID)
Conditions
Interventions
Ozone therapy group:the subjects received not only routine treatment according to their condition, but also ozone therapy (autohemotransfusion). The amount of venous blood collected was 100ml on the f
Normal therapy group:the subjects received routine treatment according to their condition without ozone therapy.
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) male or female adults, with age of 18 -70 years; (2) having been infected with confirmed SARSCoV-2 infection three months ago; (3) having persistent symptoms from onset and lasting for at least 4 weeks which cannot be explained by an alternative diagnosis; (4) the body temperature has returned to normal after the acute period treatment, in the recovery period but still have symptoms, such as cough, expectoration, sore throat, fatigue, smell disorder, muscle soreness, etc; or there are still residual imaging features remained after COVID-19 infection; or there are still psychological symptoms remained such as insomnia, anxiety, irritability, sweating, etc; (5) The participant himself signs the informed consent form and agrees to collect the clinical samples.
Exclusion criteria
Exclusion criteria: (1)Glucose-6-phosphate dehydrogenase deficiency (favism); (2)Toxic diffuse goiter (Graves' disease); (3)Thrombocyte less than 50×109/L, severe coagulation disorder; (4)Severe Unstable cardiovascular disease, myocardial infarction; (5)Acute alcoholism; (6)Massive blood loss, acute bleeding, anemia (<90 g/L); (7)Fluid and electrolyte disorders; (8)Epileptic seizures; (9)Patients with hemochromatosis, copper or iron therapy; (10)Allergy to anticoagulant (sodium citrate); (11)Pregnancy; (12)Severe hepatic insufficiency; (13)Women with menstruation; (14)Cases of poor survival, only hospice care, or deep coma unresponsive to supportive care within three hours of admission; (15)Participants withdraw from the study: 1) at their own request or at the request of their legally representatives; 2) participate in another clinical trial during the treatment phase; 3) the researchers believe that continuing the study will damage the health of the subjects; 4) in the event of serious adverse events or concurrent diseases, the researchers believe that they cannot continue to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comprehensive symptom score;Lung function test;Radiographic score of chest CT; | — |
Secondary
| Measure | Time frame |
|---|---|
| laboratory results;STOP-Bang, ESS, PSQI, ISI;Anxiety and depression mood scale score; | — |
Countries
China
Contacts
Public ContactHu Ke
Renmin Hospital of Wuhan University
Outcome results
None listed